Post-translational Modifications and Protein Quality Control in Motor Neuron and Polyglutamine Diseases

Overview

Journal Front Mol Neurosci

Specialty Molecular Biology

Date 2017 Apr 15

PMID 28408866

Citations 29

Authors

Fabio Sambataro

Maria Pennuto

Affiliations

Soon will be listed here.

Abstract

Neurodegenerative diseases, including motor neuron and polyglutamine (polyQ) diseases, are a broad class of neurological disorders. These diseases are characterized by neuronal dysfunction and death, and by the accumulation of toxic aggregation-prone proteins in the forms of inclusions and micro-aggregates. Protein quality control is a cellular mechanism to reduce the burden of accumulation of misfolded proteins, a function that results from the coordinated actions of chaperones and degradation systems, such as the ubiquitin-proteasome system (UPS) and autophagy-lysosomal degradation system. The rate of turnover, aggregation and degradation of the disease-causing proteins is modulated by post-translational modifications (PTMs), such as phosphorylation, arginine methylation, palmitoylation, acetylation, SUMOylation, ubiquitination, and proteolytic cleavage. Here, we describe how PTMs of proteins linked to motor neuron and polyQ diseases can either enhance or suppress protein quality control check and protein aggregation and degradation. The identification of molecular strategies targeting these modifications may offer novel avenues for the treatment of these yet incurable diseases.

Citing Articles

Prediction of protein interactions with function in protein (de-)phosphorylation.

Vagiona A, Notopoulou S, Zdrahal Z, Goncalves-Kulik M, Petrakis S, Andrade-Navarro M PLoS One. 2025; 20(3):e0319084.

PMID: 40029919 PMC: 11875375. DOI: 10.1371/journal.pone.0319084.

Peripheral sequestration of huntingtin delays neuronal death and depends on N-terminal ubiquitination.

Boulos A, Maroun D, Ciechanover A, Ziv N Commun Biol. 2024; 7(1):1014.

PMID: 39155290 PMC: 11330980. DOI: 10.1038/s42003-024-06733-1.

Editorial: The role of posttranslational modifications in polyglutamine diseases.

Weber J, Costa M, Scaglione K, Todi S, Nguyen H Front Mol Neurosci. 2023; 16:1271226.

PMID: 37654791 PMC: 10466034. DOI: 10.3389/fnmol.2023.1271226.

Network models of protein phosphorylation, acetylation, and ubiquitination connect metabolic and cell signaling pathways in lung cancer.

Ross K, Zhang G, Akcora C, Lin Y, Fang B, Koomen J PLoS Comput Biol. 2023; 19(3):e1010690.

PMID: 36996232 PMC: 10089347. DOI: 10.1371/journal.pcbi.1010690.

LSD1/PRMT6-targeting gene therapy to attenuate androgen receptor toxic gain-of-function ameliorates spinobulbar muscular atrophy phenotypes in flies and mice.

Prakasam R, Bonadiman A, Andreotti R, Zuccaro E, Dalfovo D, Marchioretti C Nat Commun. 2023; 14(1):603.

PMID: 36746939 PMC: 9902531. DOI: 10.1038/s41467-023-36186-9.

References

Lieberman A, Harmison G, Strand A, Olson J, Fischbeck K . Altered transcriptional regulation in cells expressing the expanded polyglutamine androgen receptor. Hum Mol Genet. 2002; 11(17):1967-76. DOI: 10.1093/hmg/11.17.1967. View

Ratovitski T, Arbez N, Stewart J, Chighladze E, Ross C . PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease (HD). Cell Cycle. 2015; 14(11):1716-29. PMC: 4615115. DOI: 10.1080/15384101.2015.1033595. View

Hasegawa M, Arai T, Nonaka T, Kametani F, Yoshida M, Hashizume Y . Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol. 2008; 64(1):60-70. PMC: 2674108. DOI: 10.1002/ana.21425. View

Minamiyama M, Katsuno M, Adachi H, Waza M, Sang C, Kobayashi Y . Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet. 2004; 13(11):1183-92. DOI: 10.1093/hmg/ddh131. View

Mookerjee S, Papanikolaou T, Guyenet S, Sampath V, Lin A, Vitelli C . Posttranslational modification of ataxin-7 at lysine 257 prevents autophagy-mediated turnover of an N-terminal caspase-7 cleavage fragment. J Neurosci. 2009; 29(48):15134-44. PMC: 2907146. DOI: 10.1523/JNEUROSCI.4720-09.2009. View

Liachko N, Guthrie C, Kraemer B . Phosphorylation promotes neurotoxicity in a Caenorhabditis elegans model of TDP-43 proteinopathy. J Neurosci. 2010; 30(48):16208-19. PMC: 3075589. DOI: 10.1523/JNEUROSCI.2911-10.2010. View

Hebron M, Chen W, Miessau M, Lonskaya I, Moussa C . Parkin reverses TDP-43-induced cell death and failure of amino acid homeostasis. J Neurochem. 2013; 129(2):350-61. PMC: 3982293. DOI: 10.1111/jnc.12630. View

DiFiglia M, Sapp E, Chase K, Davies S, Bates G, Vonsattel J . Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science. 1997; 277(5334):1990-3. DOI: 10.1126/science.277.5334.1990. View

Al-Ramahi I, Lam Y, Chen H, de Gouyon B, Zhang M, Perez A . CHIP protects from the neurotoxicity of expanded and wild-type ataxin-1 and promotes their ubiquitination and degradation. J Biol Chem. 2006; 281(36):26714-24. DOI: 10.1074/jbc.M601603200. View

10.

Niikura T, Kita Y, Abe Y . SUMO3 modification accelerates the aggregation of ALS-linked SOD1 mutants. PLoS One. 2014; 9(6):e101080. PMC: 4074151. DOI: 10.1371/journal.pone.0101080. View

11.

Jorgensen N, Andresen J, Lagalwar S, Armstrong B, Stevens S, Byam C . Phosphorylation of ATXN1 at Ser776 in the cerebellum. J Neurochem. 2009; 110(2):675-86. PMC: 2754139. DOI: 10.1111/j.1471-4159.2009.06164.x. View

12.

Liachko N, McMillan P, Guthrie C, Bird T, Leverenz J, Kraemer B . CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration. Ann Neurol. 2013; 74(1):39-52. PMC: 3775949. DOI: 10.1002/ana.23870. View

13.

Tradewell M, Yu Z, Tibshirani M, Boulanger M, Durham H, Richard S . Arginine methylation by PRMT1 regulates nuclear-cytoplasmic localization and toxicity of FUS/TLS harbouring ALS-linked mutations. Hum Mol Genet. 2011; 21(1):136-49. DOI: 10.1093/hmg/ddr448. View

14.

Zhou Y, Liao S, Luo Y, Tang J, Wang J, Lei L . SUMO-1 modification on K166 of polyQ-expanded ataxin-3 strengthens its stability and increases its cytotoxicity. PLoS One. 2013; 8(1):e54214. PMC: 3561348. DOI: 10.1371/journal.pone.0054214. View

15.

Schilling B, Gafni J, Torcassi C, Cong X, Row R, LaFevre-Bernt M . Huntingtin phosphorylation sites mapped by mass spectrometry. Modulation of cleavage and toxicity. J Biol Chem. 2006; 281(33):23686-97. DOI: 10.1074/jbc.M513507200. View

16.

Liachko N, McMillan P, Strovas T, Loomis E, Greenup L, Murrell J . The tau tubulin kinases TTBK1/2 promote accumulation of pathological TDP-43. PLoS Genet. 2014; 10(12):e1004803. PMC: 4256087. DOI: 10.1371/journal.pgen.1004803. View

17.

Blanc R, Richard S . Arginine Methylation: The Coming of Age. Mol Cell. 2017; 65(1):8-24. DOI: 10.1016/j.molcel.2016.11.003. View

18.

Nucifora Jr F, Sasaki M, Peters M, Huang H, Cooper J, Yamada M . Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science. 2001; 291(5512):2423-8. DOI: 10.1126/science.1056784. View

19.

Ellerby L, Hackam A, Propp S, Ellerby H, Rabizadeh S, Cashman N . Kennedy's disease: caspase cleavage of the androgen receptor is a crucial event in cytotoxicity. J Neurochem. 1999; 72(1):185-95. DOI: 10.1046/j.1471-4159.1999.0720185.x. View

20.

Palazzolo I, Nedelsky N, Askew C, Harmison G, Kasantsev A, Taylor J . B2 attenuates polyglutamine-expanded androgen receptor toxicity in cell and fly models of spinal and bulbar muscular atrophy. J Neurosci Res. 2010; 88(10):2207-16. PMC: 3881232. DOI: 10.1002/jnr.22389. View